Minerva Neurosciences (NERV) Treasury Shares (2013 - 2020)
Minerva Neurosciences posted quarterly Treasury Shares of $48650.0 for Q3 2020, down 61.78% year-on-year from $127300.0 in Q4 2019, and little changed on a QoQ basis from $48650.0 in Q2 2020.
Minerva Neurosciences (NERV) has 7 years of Treasury Shares data on file, last reported at $48650.0 in Q3 2020.
- For the quarter ending Q3 2020, Treasury Shares fell 61.78% year-over-year to $48650.0; the trailing twelve-month figure through Sep 2020 stood at $48650.0 (down 61.78% YoY), and the FY2019 full-year result was $68650.0, down 46.07% from the prior year.
- Treasury Shares for Q3 2020 stood at $48650.0, roughly flat from $48650.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $3.9 million in Q3 2017 and bottomed at $48650.0 in Q2 2020.
- The 5-year median for Treasury Shares is $156625.0 (2018), against an average of $607497.6.
- The widest annual swing landed in 2017, when Treasury Shares surged 1672.43%; it then tumbled 96.73% in 2018.
- A 5-year view of Treasury Shares shows it stood at $219600.0 in 2016, then soared by 1672.43% to $3.9 million in 2017, then sank by 96.73% to $127300.0 in 2018, then slumped by 46.07% to $68650.0 in 2019, then decreased by 29.13% to $48650.0 in 2020.
- The last three Treasury Shares figures came in at $48650.0 (Q3 2020), $48650.0 (Q2 2020), and $68650.0 (Q1 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 265,401.92 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 700,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 34.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 48,650.00 |
| Sep 30, 2020 | 48,650.00 |
| Jun 30, 2020 | 48,650.00 |
| Jun 30, 2020 | 48,650.00 |
| Mar 31, 2020 | 68,650.00 |
| Mar 31, 2020 | 68,650.00 |
| Dec 31, 2019 | 68,650.00 |
| Dec 31, 2019 | 68,650.00 |
| Sep 30, 2019 | 127,300.00 |
| Sep 30, 2019 | 127,300.00 |
| Jun 30, 2019 | 127,300.00 |
| Jun 30, 2019 | 127,300.00 |
| Mar 31, 2019 | 127,300.00 |
| Mar 31, 2019 | 127,300.00 |
| Dec 31, 2018 | 127,300.00 |
| Dec 31, 2018 | 127,300.00 |
| Sep 30, 2018 | 185,950.00 |
| Sep 30, 2018 | 185,950.00 |
| Jun 30, 2018 | 185,950.00 |
| Jun 30, 2018 | 185,950.00 |
| Mar 31, 2018 | 185,950.00 |
| Mar 31, 2018 | 185,950.00 |
| Dec 31, 2017 | 3.89 Mn |
| Dec 31, 2017 | 3.89 Mn |
| Sep 30, 2017 | 3.89 Mn |
| Sep 30, 2017 | 3.89 Mn |
| Jun 30, 2017 | 194,600.00 |
| Jun 30, 2017 | 194,600.00 |
| Mar 31, 2017 | 219,600.00 |
| Mar 31, 2017 | 219,600.00 |
| Dec 31, 2016 | 219,600.00 |
| Dec 31, 2016 | 219,600.00 |
| Dec 31, 2014 | 348,926.00 |
| Dec 31, 2014 | 348,926.00 |
| Sep 30, 2014 | 348,926.00 |
| Sep 30, 2014 | 348,926.00 |
| Jun 30, 2014 | 348,926.00 |
| Jun 30, 2014 | 348,926.00 |
| Mar 31, 2014 | 926,604.00 |
| Mar 31, 2014 | 926,604.00 |
| Dec 31, 2013 | 1.28 Mn |
| Dec 31, 2013 | 1.28 Mn |